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Abstract
Background: Elf5, an epithelial specific Ets transcription factor, plays a crucial role in the pregnancy-associated development
of the mouse mammary gland. Elf5
2/2 embryos do not survive, however the Elf5
+/2 mammary gland displays a severe
pregnancy-associated developmental defect. While it is known that Elf5 is crucial for correct mammary development and
lactation, the molecular mechanisms employed by Elf5 to exert its effects on the mammary gland are largely unknown.
Principal Findings: Transcript profiling was used to investigate the transcriptional changes that occur as a result of Elf5
haploinsufficiency in the Elf5
+/2 mouse model. We show that the development of the mouse Elf5
+/2 mammary gland is
delayed at a transcriptional and morphological level, due to the delayed increase in Elf5 protein in these glands. We also
identify a number of potential Elf5 target genes, including Mucin 4, whose expression, is directly regulated by the binding of
Elf5 to an Ets binding site within its promoter.
Conclusion: We identify novel transcriptional targets of Elf5 and show that Muc4 is a direct target of Elf5, further elucidating
the mechanisms through which Elf5 regulates proliferation and differentiation in the mammary gland.
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Introduction
The mammary gland is one of a few organs able to undergo
repeated phases of growth, differentiation and regression. At the
onset of puberty in the female, the increase in ovarian steroids
induces elongation and side-branching of the rudimentary
mammary ductal system which formed embryonically. Club-
shaped terminal end buds (TEBs) develop at the ends of the
developing ducts which consist of a layer of cap cells at the
proceeding edge and multiple inner body cell layers. These TEBs
are the proliferating edge of the ducts penetrating the mammary
fat pad and regress once the development of the ductal tree is
complete. Some differentiation of the ductal system occurs at
this stage, resulting in a compact glandular structure. The gland
then remains relatively inactive until a pregnancy occurs [reviewed
in 1, 2].
Lobuloalveolar development commences with the onset of
pregnancy and is associated with the formation of spherical alveoli
along the ductal network that formed during puberty. By the end
of pregnancy, the ductal tree is densely populated with alveoli.
Functional differentiation of the alveoli commences during late
pregnancy and this process is complete by parturition to enable
lactation. The mammary gland continues to produce milk until
weaning, at which time the gland regresses in a process known
as involution. This cyclical development of the mammary gland
is controlled by various hormonal and genetic signals [reviewed in
1, 2]
Using a genetic knock-out mouse model, we identified a key role
for the epithelial-specific Ets transcription factor, Elf5, in the
development of the mammary gland during pregnancy [3]. The
complete lack of Elf5 resulted in a lack of the extraembryonic
ectoderm which led to early embryonic death [4]. Mice carrying
one functional copy of the Elf5 gene (Elf5
+/2) were viable.
However, unlike their wildtype littermates, Elf5
+/2 females were
unable to support their offspring due to a pregnancy-associated
mammary gland developmental defect, which prohibited these
dams from lactating [3]. Elf5 expression was downregulated in the
Prlr
+/2 mammary gland while Prlr expression remained un-
changed in the Elf5
+/2 mammary gland [3], indicating that Elf5
acts downstream of the Prlr in the Prl signalling cascade. This was
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whereby ectopic expression of Elf5 in the Prlr-null mammary
epithelium was sufficient to rescue the developmental defect
observed in the Prlr-null mice [5]. While it is known that Elf5 is
able to activate the promoter of the milk protein gene whey acidic
protein (Wap) [6], the mechanisms employed by Elf5 to induce its
effect on mammary epithelial cell proliferation and differentiation
are largely unknown. Here, we have used transcript profiling to
investigate the transcriptional changes that occur as a result of Elf5
haploinsufficiency as a first step in determining the mechanisms of
Elf5 action and the targets of this transcription factor. We show
that mammary gland development in the Elf5
+/2 female mouse is
delayed during pregnancy due to the delayed increase in Elf5
protein expression in these glands. We identify a number of
potential Elf5 target genes including Muc4, which we show is
directly regulated by the binding of Elf5 to its promoter.
Methods
Mice
All work performed using mice as part of this study was
approved by the appropriate Monash University Animal Ethics
Committee and as such, all animal work followed the committee’s
guidelines and procedures. Mice were housed in a windowless
room with controlled temperature (22uC62uC), on a 12 hour light
and dark cycle and were fed ad libitum. Pregnancy was determined
by the presence of a vaginal plug and the day of detection
designated 0.5 days post coitum (dpc). Mammary glands were
collected between 11am and 1pm to control for circadian Prl
release. Mice targeted at the Elf5 locus were generated previously
in our laboratory [3] and backcrossed for more than 10
generations onto a C57Bl/6 genetic background.
Microarray analysis
Microarray analysis of the Elf5
+/2 mammary glands was
performed using a common reference experimental design.
Abdominal mammary glands (minus the associated lymph nodes)
of2 micewerepooled(toensureenoughmaterialwasobtainedfrom
virgin samples) and total RNA extracted using a RNeasy maxi kit
(Qiagen) according to the manufacturer’s instructions. RNA for use
as the reference was extracted from eight embryonic (17.5dpc)
C57Bl/6 mice using the same method. The RNA samples were
sent to the Adelaide Microarray Facility for the remainder of the
processing (see website for processing protocols: http://www.
microarray.adelaide.edu.au). Five stages of mammary gland
development (virgin, 8.5dpc, 10.5dpc, 14.5dpc and 16.5dpc), in
two distinct genotypes (Elf5
+/+ and Elf5
+/2) were examined in
triplicate. A total of 30 array slides was used to examine 3
independent pooled RNA samples per genotype per timepoint. The
slides chosen for this study were 22,000 element Compugen array
chips which were spotted with single stranded oligonucleotides of 60
base pair length. Processed slides were scanned and the resulting
images analysed using Digital Genome (Molecularware). Data
analysis was performed using the Genespring software suite
(Agilent). All data produced is MIAME compliant and has been
deposited in the NCBI Gene Expression Omnibus database under
series accession number GSE23373 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE23373).
RNA extraction and gene expression analysis
Total RNA was extracted from mammary glands using Trizol
reagent (Invitrogen) according to the manufacturer’s instructions.
RNA was treated with DNase (Promega) before being converted to
cDNA using Superscript III (Invitrogen) and random primers
(Promega). Quantitative real-time RT-PCR was performed on
samples using TaqMan Gene Expression Assays (ABI) specific for
Elf5 and Muc4. Relative expression was determined using the
DDCT method [reviewed in 7], with the expression of the genes of
interest first being normalised to the level of 18S expression.
Protein extraction and Western blotting
Snap frozen tissue was homogenised in tissue lysis buffer
(50 mM Hepes pH 7.5, 100 mM NaCl, 1 mM EDTA, 10% (v/v)
glycerol, 0.5% (v/v) Nonidet-P40, Roche protease inhibitor
cocktail tablet), and centrifuged to remove any insoluble material.
Protein (50 mg) was separated using SDS-PAGE. Fractionated
proteins were transferred to polyvinylidene fluoride (PVDF)
membrane (Immobilon-P, Millipore) and membranes blocked for
1 hour at room temperature with 5% skim milk/TBST, before
incubating with primary antibody overnight at 4uC. All secondary
antibodies were conjugated to horseradish peroxidase and
obtained from Dako. Membranes were incubated with Super-
Signal West Pico chemiluminescent substrate (Pierce), after which
they were exposed to Hyperfilm ECL film (Amersham Pharmacia),
to detect chemiluminescence. Antibodies used in this study: anti-
Elf5 (N-20) (Santa Cruz, catalogue number SC-9645); anti-mouse
milk specific proteins (Accurate Chemical and Scientific Corpo-
ration, catalogue number YNRMMSP). Blotting for Muc4 was
performed as described previously [8]
Recombinant ELF5 protein preparation
Recombinant ELF5 protein was made by cloning a truncated
ELF5 cDNA into the BamHI/SacII sites of the pQE-30 (Qiagen)
vector enabling the production of a truncated Elf5 (D33) protein
fused to a (HIS)6 tag. Primers used to amplify the truncated cDNA
were as follows: hELF5D33BamHI_F: 59 CGTAGGATCCGCC-
TTTGAGCATCAGACAG 39 and hELF5D33SacI_R: 59 CA-
TGGAGCTCAGCTTGTCTTCCTGCCACCC 39. TALON
beads (Clontech) were used to purify the protein as per the
manufacturer’s instructions.
Cell transfection and reporter assays
The human breast carcinoma cell line T47D (ATCC) was
grown in 1x RPMI with 10% (v/v) FCS plus 1% (v/v) penicillin/
streptomycin and maintained in culture at 37uC, 5% CO2. T47D
cells were plated in a 24 well plate at a density of 5610
4 cells/well
in complete media. These cells were left to settle at 37uC, 5% CO2
for 24 hours before being transiently transfected with a total of
500 ng of DNA using the FuGENE6 transfection reagent
according to the manufacturer’s instructions (using a 1:3
DNA:FuGENE ratio). Cells were transfected with a MUC4
promoter-luciferase reporter construct (wild-type or mutated)
[9,10] along with an ELF5 expression vector and a b-galactosidase
expression construct that was used as a measure of transfection
efficiency. The cells were left for 48 hours before being harvested
for luciferase and b-galactosidase assays. Luciferase reporter gene
assays were performed using the Constant light signal kit (Roche)
according to the manufacturer’s instructions. b-galactosidase
assays were performed by incubating a portion of the cell lysate
with an equal volume of b-galactosidase sample buffer (0.1 M b-
mercaptoethanol, 2 mM MgCl2,8 8mMN a 2HPO4.2H2O, 90 mM
NaH2PO4.2H2O, 4.5 mM 2-nitrophenyl-b-D-galactopyraniside),
at 37uC for 1–2 hours or until colour developed. Luciferase and b-
galactosidase assays were read on a Flourostar Optima plate
reader (BMG). Absorbance for the b-galactosidase assay was read
at 415 nm. Luciferase readings were normalised by division with
the corresponding b-galactosidase reading.
Elf5 Mammary Gland Development
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Snap frozen mammary glands, excised from 16.5dpc mice, were
crushed in a mortar and pestle under liquid nitrogen, to a fine
powder which was then mixed with ice-cold buffer A (10 mM
Hepes pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 500 mM PMSF,
500 mM DTT 2900 ml per gland). The suspension was centri-
fuged, and the pellet resuspended in 20 ml of buffer A with the
addition of Nonidet-P40 (to 0.15% v/v) and incubated on ice for
10 mins. The sample was centrifuged and the pellet resuspended
in 15 ml of ice-cold buffer C (20 mM Hepes pH 7.9, 420 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% (v/v) glycerol,
500 mM PMSF) before centrifugation and transfer of the
supernatant to a fresh tube containing 40 ml of ice-cold buffer D
(10 mM Hepes pH 7.9, 50 mM KCl, 0.2 mM EDTA, 20% (v/v)
glycerol, 500 mM PMSF, 0.5 mM DTT).
Electrophoretic mobility shift assay (EMSA)
Short double stranded oligonucleotides were end-labelled with
(c-
32P)dATP (Perkin-Elmer) using T4 polynucleotide kinase
(Promega), according to the manufacturer’s instructions. When
examining ELF5 binding to the MUC4 promoter, an oligonucle-
otide containing the Ets site predicted at 2216 was used as a probe
59CCACCAGGAAAGAAAACACCG 39. A mutant sequence
where GGAA was changed to AAAA was also used. Nuclear
extract (4 mg) or recombinant ELF5 protein (200 ng), with 1x
bandshift binding buffer (40% (v/v) glycerol, 10 mM EDTA,
50 mM DTT, 100 mM Tris pH 7.5, 1 M NaCl, 1 mg/ml BSA)
and a 100-fold molar excess of unlabelled competitor oligonucle-
otide were combined in a total volume of 20 ml. After 30 mins at
room temperature, 30,000 counts per minute (cpm) of radiola-
belled oligonucleotide probe was added and incubation continued
for an additional 30 mins. Reactions were electrophoresed on
polyacrylamide gels which were dried under vacuum onto blotting
paper and then exposed to X-ray film.
Results
Transcript profiling indicated that pregnancy-associated
development of the Elf5
+/2 mammary gland was delayed
The changes in gene expression that occur as a result of the loss
of one Elf5 allele were investigated by transcript profiling. Having
previously observed that the morphological development of the
Elf5
+/2 mammary gland appears stunted [3], we sought to
examine this potential developmental delay by transcriptional
profiling. Profiles were generated for both the Elf5
+/+ and Elf5
+/2
mammary glands at 5 stages of mammary development (virgin,
8.5dpc, 10.5dpc, 14.5dpc and 16.5dpc). To examine the
similarities between the global transcriptional profiles of each of
the 10 experimental conditions (five stages of mammary gland
development in 2 genotypes), a dendrogram (Figure 1a) was
generated within Genespring using an average linking clustering
algorithm and a Spearman correlation similarity measure.
The virgin wildtype mammary gland was placed on its own
node of the dendrogram while all the other conditions were
clustered on a separate arm. The Elf5
+/2 virgin and 8.5dpc
samples were placed together on a separate node suggesting that
they were most similar to one another, and more similar to the
other pregnant conditions rather than to the Elf5
+/+ virgin
condition. Notably, the Elf5
+/2 10.5dpc and 14.5dpc conditions
were clustered with the wildtype 8.5dpc sample, between the
wildtype virgin and wildtype 10.5dpc samples, indicating that the
expression profile of the 10.5dpc and 14.5dpc heterozygous gland
was most similar to an earlier timepoint in the wildtype gland. Not
surprisingly, the 14.5dpc and 16.5dpc wildtype conditions were
most similar to one another. The Elf5
+/2 16.5dpc condition was
placed on a separate node, but adjacent to the wildtype 14.5dpc
and 16.5dpc conditions, suggesting that the gene expression profile
of the Elf5
+/2 16.5dpc mammary gland had ‘caught up’ with the
wildtype to some extent, although obvious gene expression
differences remained.
Figure 1. Comparing the Transcriptional profiles of Elf5
+/+ and Elf5
+/2 mammary glands. A. A condition dendrogram was generated within
the Genespring software suite using an average linking clustering algorithm and a Spearman correlation similarity measure. Individual genes are
represented by horizontal bars, which are coloured according to their expression level relative to the virgin Elf5
+/+ (V+/+) sample. B. Principal
components analysis was performed in Genespring on all 10 conditions examined by microarray. Conditions are plotted on a 3-dimensional scatter
plot according to their variance from the first 3 components. The conditions were normalised to the V+/+ condition.
doi:10.1371/journal.pone.0013150.g001
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the dataset to examine the relationships between the transcrip-
tional profiles of the experimental conditions (Figure 1b). A three-
dimensional scatter plot mapping the experimental conditions by
the first three principal components showed that the Elf5+/+
conditions are separated based upon whether they originated from
a pregnant animal or not i.e. the virgin Elf5+/+ condition was
placed alone, whereas the 4 conditions representing pregnant
Elf5+/+ animals were clustered together. The 4 pregnant
conditions showed increasingly greater variance from the first
component in accordance with the stage of pregnancy. The
separation of the wildtype pregnant conditions according to the
stage of pregnancy also occurred in the direction of the third
component. Here, the later the stage of pregnancy they
represented the closer they were placed to 1 on the axis of the
third component.
Supporting the condition dendrogram, the virgin Elf5
+/2
sample was positioned closer to the pregnant samples of both
genotypes than to the wildtype virgin sample. The Elf5
+/2 14.5dpc
condition was placed closest to the 8.5dpc and 10.5dpc wildtype
conditions suggesting that it had greatest similarity to the wildtype
mammary gland at earlier stages of pregnancy. The 16.5dpc
Elf5
+/2 condition was positioned closest to the 14.5dpc wildtype
sample indicating that the expression profile of the Elf5
+/2 gland is
becoming more similar to a more developed gland after 14.5dpc.
It should be noted however that morphologically and functionally
the Elf5
+/2 gland remains underdeveloped compared to the
wildtype gland [3].
Expression of milk proteins is delayed in the Elf5
+/2
mammary gland
Milk protein expression in the mammary gland can be used as a
measure of differentiation. Expression of a-casein and b-casein
proteins was first evident at 12.5dpc in the Elf5+/+ mammary
gland, while Wap appeared at 14.5dpc (Figure 2a). In contrast, in
the Elf5
+/2 mammary gland, expression of a- and b-caseins was
not apparent until 16.5dpc. This result supports the notion that at
14.5dpc the Elf5
+/2 mammary gland is most similar to a very early
stage wildtype gland, while at 16.5dpc the Elf5
+/2 gland is more
like a gland that has entered the differentiation program. Indeed,
the milk protein expression profile of the Elf5
+/2 16.5dpc gland is
similar to the wildtype 12.5dpc. gland.
Chronologically, the milk protein gene a-lactalbumin is the last
milk protein gene to be expressed during pregnancy-associated
mammary gland development [11]. The expression of a-lactalbumin
has been used to determine whether a mammary gland has
progressed from the first stage of lactogenesis known as the
secretory initiation phase to the second stage, the secretory
activation phase [12]. To determine whether the Elf5
+/2
mammary gland had proceeded through secretory initiation, we
examined the level of a-lactalbumin expression in the Elf5
+/2
mammary gland in our microarray experiment (Figure 2b). Unlike
the wildtype gland, at 14.5dpc there was no significant increase in
a-lactalbumin expression in the Elf5
+/2 gland and furthermore, the
static expression level of a-lactalbumin in the Elf5
+/2 gland
suggested that the Elf5
+/2 gland had not proceeded through
secretory initiation by 16.5dpc.
Pregnancy associated increase of Elf5 expression is
delayed in the Elf5
+/2 mammary gland
To examine the correlation between Elf5 expression levels and
the gene expression profiles observed we measured Elf5 mRNA
and protein in Elf5
+/+ and Elf5
+/2 mammary glands at various
stages of pregnancy (Figure 3). In the Elf5
+/+ mammary gland Elf5
mRNA expression increased during the course of pregnancy,
reaching a 49 fold induction in expression by 16.5dpc compared to
its expression in the wildtype virgin gland (Figure 3a). Others have
shown a similar Elf5 expression pattern during pregnancy-
associated mammary gland development in C57Bl/6 x 129SVPas
mice [5]. Expression of Elf5 remained relatively low in the Elf5
+/2
mammary glands throughout early pregnancy but began to
increase at the later timepoints (Figure 3a). In the Elf5
+/2 gland
at 14.5dpc, Elf5 expression increased by 5.94 fold with respect to
the virgin wildtype gland, compared with 34.72 fold in the Elf5
+/+
gland (p,0.001). Likewise, at 16.5dpc Elf5 expression in the
Elf5
+/2 mammary gland had only increased by 13.69 fold (with
respect to the virgin wildtype condition), whereas in the pregnant
wildtype mammary gland at this stage, Elf5 expression was
increased by 49.08 fold (p,0.001). In the wildtype mammary
gland, Elf5 protein was detected at all time points examined and its
expression increased throughout pregnancy as previously de-
scribed (Figure 3b) [3,5]. Similar to its mRNA expression pattern,
Elf5 protein was detected in all Elf5
+/2 mammary gland samples,
however the levels of Elf5 expression remained comparable to that
in the 10.5dpc Elf5
+/2 mammary gland until 16.5dpc where it
increased slightly (Figure 3b).
Identification of potential Elf5 target genes
To identify potential Elf5 targets, gene expression changes due
to Elf5 heterozygosity were examined at each individual timepoint.
Figure 2. Differentiation of the Elf5
+/2 mammary gland during pregnancy is delayed. A. Western blot analysis of the milk proteins a-
casein, b-casein and Wap in the mammary glands of Elf5
+/+ and Elf5
+/2 mice. B. Lactalbumin (Lalba) expression in the mammary glands of Elf5
+/+ and
Elf5
+/2 mice measured by microarray analysis. Expression is shown relative to the virgin Elf5
+/+ sample.
doi:10.1371/journal.pone.0013150.g002
Elf5 Mammary Gland Development
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of these changes can be found in supplementary Tables S1, S2, S3,
S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14 with
accompanying descriptions in supplementary files S1 and S2.
We also used clustering algorithms to organise our data. This type
of analysis assembles genes with common patterns of expression
into groups, called clusters. Our rationale for choosing clustering
was that genes grouped according to their similar expression
patterns were likely to be co-regulated. By clustering our data set
and identifying the cluster containing Wap, a known Elf5 target
gene [6], we anticipated identifying other Elf5 targets.
Employing two commonly used algorithms, K-means and self
organising maps (SOMs), we searched for the genes that clustered
with Wap. Independent K-means clustering was performed 10
times, the first time with a K value of 5, after which the K value
was increased by 5 each time until 50 clusters was reached. Of the
10 K-means analyses performed, K=15 produced the highest
explained variability (70.435%) and for this reason was used in the
remainder of our analysis. We also generated multiple SOMs
(464, 465, 466, 565, 566 and 666), with the 666 SOM
generating the highest explained variability (79.419%). We
identified the clusters from each of the 15 cluster K-means and
the 666 SOM that contained Wap and compared the two lists to
identify 23 common genes (Figure 4). The expression of all 23 of
these genes was downregulated at all timepoints in the pregnant
Elf5
+/2 gland compared to the pregnant wildtype gland.
Next we used the DAVID functional annotation clustering tool
(http://david.abcc.ncifcrf.gov/home.jsp) [13] to determine wheth-
er any gene ontology classification was over-represented in the 23
genes that consistently clustered with Wap (Table 1). The gene
ontology (GO) terms signal, extracellular space, cellular lipid
metabolism, lipid metabolism and glycoprotein were all identified
as being significantly enriched in the list with each having a p-
value less than 0.05. The GO terms signal and extracellular space
defined under annotation cluster 1, represented 34.78% of the 23
genes and included Csng, Lamp1, Col9a1, Wap, Btn1a1, Glycam1,
Aplp and Pp11r. The terms cellular lipid metabolism and lipid
metabolism defined under annotation cluster 2, represented
17.39% of the genes and included Cte1, Lrat, Fabp3, Alox12e. The
term glycoprotein was also significantly enriched (annotation
cluster 3) and represented the genes Lamp1, Col9a1, Btn1a1,
Glycam1, Aplp and Ighg.
Figure 3. Elf5 expression profile during pregnancy associated mammary gland development. A. Elf5 mRNA expression in in the
mammary glands of Elf5
+/+ and Elf5
+/2 mice measured by qRT-PCR. Expression is shown relative to the average expression of Elf5 in the Elf5
+/+ virgin
samples. ***p,0.001. n=3. B. Western blot analysis of Elf5 protein expression in the mammary glands of Elf5
+/+ and Elf5
+/2 mice during pregnancy.
doi:10.1371/journal.pone.0013150.g003
Figure 4. Genes that clustered with the known Elf5 target gene
Wap. Expression profiles of the 23 genes that consistently clustered
with Wap using 2 clustering algorithms, in the mammary glands of
Elf5
+/+ and Elf5
+/2 mice. Gene expression is shown relative to expression
in the virgin Elf5
+/+ condition.
doi:10.1371/journal.pone.0013150.g004
Elf5 Mammary Gland Development
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of potential Elf5 target genes
We hypothesised that the promoter of a gene whose expression
is directly regulated by Elf5 would contain an Ets binding site –
and more specifically, an Ets site with a specific flanking sequence
reported to be preferred by Elf5 [59(A/C)GGAA(G/A)(T/G)(A/
G)NNC 39] [14]. The predicted promoter regions (1000 bp
upstream of the transcriptional start site) of 20 of the 23 genes
clustered with Wap were obtained using EZretrieve. (http://
siriusb/umdnj.edu:18080/EZRetrieve/index.jsp) and Promoser
(http://biowulf.bu.edu/zlab/PromoSer). The upstream sequences
for the genes Acbd7, Ighg and Gm566 were not identified by these
programs. Putative promoter sequences were searched using the
Transcriptional Element Search System (TESS), which is
accessible via the web-based Baylor College of Medicine (BCM)
Search Launcher (http://searchlauncher.bcm.tmc.edu/). Of the
20 promoter sequences searched, 5 (Wap, Muc4, Col9a1, Pp11r and
Lamp1) contained at least one putative Ets binding site. We chose
to investigate Muc4 as a potential direct transcriptional target of
Elf5 since Muc4 has a role in the pregnant mammary gland in
rodents and in humans and dysregulated expression of MUC4 has
been associated with breast cancer [15]. Moreover, MUC4 is
transcriptionally regulated by another Ets factor, PEA3 [9]. In
addition, the predicted Ets sites at nucleotide positions 2216 and
21613 (where numbering is relative to the initiating ATG) of the
human MUC4 promoter are almost identical to the preferred Elf5
binding site, with only the 39 nucleotide differing from the
predicted Elf5 preferred sequence.
Muc4 expression is decreased in the Elf5
+/2 mammary
gland
The Muc4 expression pattern observed in the microarray
analysis (Figure 5a) was confirmed by quantitative real time RT-
PCR on RNA samples distinct from those used in the microarray
experiments (Figure 5b). While there was no significant difference
in Muc4 expression between the two genotypes in the virgin,
8.5dpc or 10.5dpc glands, a 10 fold reduction in Muc4 expression
was observed at 14.5dpc in the Elf5
+/2 gland compared to the
wildtype (55.16 fold in the wildtype compared with 5.26 fold in
Elf5
+/2;p ,0.001). A significant 2.3 fold decrease in Muc4
expression was observed in the Elf5
+/2 gland at 16.5dpc compared
with the 16.5dpc wildtype gland (43.65 fold in the wildtype gland
compared with 18.76 fold in Elf5
+/2;p ,0.05). Correspondingly,
while Muc4 protein increased dramatically at 18dpc and was
sustained at 1dpp in the Elf5
+/+ mammary gland, Muc4 protein
was undetectable in the Elf5
+/2 mammary glands at these times
(Figure 5c).
Table 1. Functional annotation clustering of the 23 genes




% of the 23 genes
represented p-value
Annotation cluster 1
Signal 7 30.43% 0.0023
Extracellular space 8 34.78% 0.0068
Annotation cluster 2
Cellular lipid metabolism 4 17.39% 0.0073
Lipid metabolism 4 17.39% 0.012
Annotation cluster 3
Glycoprotein 6 26.09% 0.0234
doi:10.1371/journal.pone.0013150.t001
Figure 5. Examining Muc4 as a potential Elf5 target gene. A. Muc4 mRNA expression in the mammary glands of Elf5
+/+ and Elf5
+/2 mice
measured by microarray analysis. Expression is shown relative to the virgin Elf5
+/+ condition. B. Muc4 expression in the mammary glands of Elf5
+/+ and
Elf5
+/2 mice measured by qRT-PCR. Expression is shown relative to the average expression of Muc4 in the virgin Elf5
+/+ samples. ***p,0.001; *p,0.05.
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site at 2216
The full-length proximal hMUC4 promoter (2461/21) and a
truncated proximal promoter (2219/21) were used to drive a
luciferase reporter gene [10]. The proximal promoter contains a
predicted ELF5-preferred ETS binding site at position 2216, in
addition to a predicted ETS binding site at 2349 [14]. The human
breast carcinoma cell line T47D was used since it expresses MUC4
[16] and therefore contains all the factors required for MUC4
expression. Cells were transfected with the promoter constructs
alone, or co-transfected with an ELF5 expression plasmid [6]. The
full-length proximal MUC4 promoter triggered a 7.49 fold increase
in luciferase activity over the empty pGL3 vector (Figure 6a). Co-
expression of ELF5 in these cells at a 1:1 molar ratio
(ELF5:MUC4 promoter) resulted in a significant increase in
promoter activity (16.06 fold over the promoterless vector;
p,0.001). Luciferase expression driven by the truncated MUC4
proximal promoter increased 4.69 fold above the baseline of the
promoterless vector and significant increases in luciferase activity
were observed when ELF5 was over-expressed in these cells at a
0.5:1 or 1:1 (ELF5:promoter) molar ratio (p,0.001) indicating
that ELF5 was acting on the MUC4 promoter.
To confirm that ELF5 was activating the MUC4 promoter via
the preferred ELF5 binding site at nucleotide position 2216, the
promoter-luciferase reporter experiments were repeated with a
MUC4 2219/21 promoter-luciferase construct in which the Ets
Figure 6. ELF5 directly regulates MUC4 promoter activity. A. The effect of ELF5 expression on MUC4 promoter activity was tested using MUC4
promoter-luciferase reporter gene assays with different regions of the MUC4 promoter. Cells were transfected with either the promoter construct
alone or with the promoter construct plus an ELF5 expression vector at molar ratios of 1:1 or 1:0.5 (promoter-luciferase vector:ELF5 expression vector).
Luciferase expression is shown relative to the expression of the pGL3 promoterless vector. *** p,0.001; **p,0.01. n=3. B. EMSA was used to
determine whether Elf5 could bind the 2216 Ets site within the MUC4 promoter. Binding was observed (arrow) in lane 1 when a nuclear extract from
a 16.5dpc Elf5
+/+ mammary gland was incubated with a radioactively labelled oligonucleotide encompassing the 2216 Ets site from the MUC4
promoter (wt). The binding observed was not evident when the Ets site in the probe was mutated (mt) (lane 2), indicating that the upper band
represents specific binding to the Ets sequence. Binding to the wt probe was competed off with a 100-fold molar excess of unlabelled wt oligo (lane
3) but not with mt oligo (lane 4). Binding to the wt probe was not shifted with the addition of anti-ELF5 antibody (lane 5). C. The EMSA from (A) was
performed again using a D33 ELF5 recombinant protein in place of the nuclear extract. The truncated recombinant ELF5 protein bound the labelled
wt oligo (lane 1), but not the mt oligo (lane 2). Binding to the wt oligo could not be competed off with the mt oligo (lane 3), but was successfully
competed off using an excess of unlabelled wt oligo (lane 4).
doi:10.1371/journal.pone.0013150.g006
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AAAA) [9]. This 2216/21 mutant construct showed promoter
activity equivalent to that of the wildtype 2216/21 region,
indicating that basal MUC4 expression in T47D cells was not
dependant on the Ets binding site at position 2216. However,
over-expression of ELF5 failed to induce activity of the mutated
MUC4 promoter (Figure 6a), indicating that ELF5 was acting on
the Ets binding site at nucleotide position 2216.
ELF5 binds the Ets binding site at 2216 in the MUC4
promoter
To confirm that ELF5 regulated MUC4 expression by directly
binding its target sequence, we performed electrophoretic mobility
shift assays (EMSA). Two bands were evident upon incubation of
the wildtype probe with the d16.5 pregnant mammary gland
nuclear extract (Figure 6b, lane 1) indicating binding to the probe.
When a probe containing the mutated Ets binding site was used
only the lower band was evident (lane 2) suggesting that the higher
band represented specific binding. Binding to the wildtype probe
could be competed off by the addition of a 100-fold molar excess
of a non-radiolabelled wildtype probe to the nuclear extract (lane
3) while the addition of an excess of mutated non-radiolabelled
probe had no effect on binding activity (lane 4) confirming that
binding to the 2216 Ets site was specific. To determine whether it
was Elf5 in the nuclear extract binding to the site we performed a
supershift assay by adding an anti-Elf5 antibody to the nuclear
extract/probe mix. The addition of this antibody had no effect on
the mobility of the probe/protein complex (lane 5). However, it is
possible that this anti-Elf5 antibody does not function in a
supershift assay.
Since we could not determine the identity of the protein in the
nuclear extract binding the MUC4 promoter, we performed an
EMSA using recombinant ELF5 protein. Full length recombinant
ELF5 protein does not bind DNA efficiently due to the presence of
a negative regulatory domain at the amino end of the protein [17],
therefore a truncated ELF5 protein lacking 33 amino acids from
the amino terminus was produced. The D33 ELF5 protein was
able to bind the wildtype probe (Figure 6c, lane 1) but was unable
to bind the mutated probe (lane 2), indicating that the binding to
the wildtype probe was specific. Incubation with a 100-fold molar
excess of the unlabelled mutated probe did not alter binding to the
wildtype probe (lane 3) but addition of unlabelled wildtype probe
competed off all binding (lane 4).
Discussion
Elf5 plays a major role in pregnancy-associated mammary gland
development. Re-expression of Elf5 in the epithelium of the
Prlr
2/2 mammary gland restored mammary gland development
during pregnancy [5], revealing that Elf5 acts downstream of the
Prlr, presumably as a Stat5 target gene [1,2]. However for the
most part, the mechanism underpinning Elf5 function remains
unclear. We used transcript profiling to examine the transcrip-
tional changes induced by the loss of one Elf5 allele, as a first step
to defining this mechanism.
Transcript profiling revealed a delay in the development
of the Elf5
+/2 mammary gland during pregnancy
It has been proposed that Elf5 plays a major role in the co-
ordination of proliferation, differentiation and apoptosis in the
mammary epithelial cell compartment [18]. Our results, and the
phenotype of the Elf5-over-expressing mouse [19], support the
notion that Elf5 is essential for mammary epithelial cell
differentiation. We have shown that the global gene expression
profile of the mammary gland shifts upon robust expression of Elf5
protein and coincides with the first expression of milk proteins. We
observed delayed synthesis of milk proteins in the Elf5
+/2 gland
where increased expression of Elf5 protein was delayed until
16.5dpc, suggesting that these mammary glands are not entering
the differentiation phase of the developmental program until this
time.
With the exception of Wap [6], the direct transcriptional targets
of Elf5 in the mammary gland are unknown. Clustering analysis
allowed us to generate a list of 23 genes with expression profiles
similar to Wap, with six already known to play roles in the
mammary gland (Csng [20]; Glycam1 [21]; Muc4 [22]; Fabp3 [23];
Btn1a1 [24] and Cx26 [25]). Functional annotation of the 23 gene
cluster revealed a significant enrichment for genes associated with
signalling and the extracellular space, lipid metabolism and
glycoproteins.
Of the 23 genes identified through clustering analysis, only 5
contained at least one Ets binding site in the promoter region
analysed. A number of possible explanations exist. Firstly, the
remaining genes may not be direct targets of Elf5 but may be
regulated by factors which are themselves dependent on Elf5.
Secondly, it is possible that Elf5 forms a complex with one or more
other proteins and that this complex binds the promoter regions of
target genes via the binding sites of the non-Ets proteins within the
complex. Thirdly, the possibility exists that Ets binding sites
involved in the regulation of these genes are located within a
region outside of the 1000 base pairs searched in our study.
MUC4 gene expression is directly regulated by ELF5
Muc4 is a glycoprotein located within the membrane of
secretory epithelial cells [26] and its expression is dysregulated in
breast cancer [15]. Here we have shown that Muc4 expression is
significantly down-regulated in the Elf5
+/2 mammary gland
compared to the wildtype gland at 14.5dpc and 16.5dpc. In the
T47D breast cancer cell line, exogenous addition of ELF5 was able
to induce expression from the MUC4 promoter. Furthermore, we
have shown that ELF5 is able to directly bind the MUC4 promoter
via a preferred ELF5 binding site.
Interestingly, the binding site used by ELF5 to regulate MUC4
expression is the same site used by another Ets factor, PEA3, to
regulate MUC4 expression in the pancreas [9], in HC11 mouse
mammary epithelial cells and in MAT-B1 and MAT-C1 rat
mammary tumour cells [27], suggesting some functional redun-
dancy. However, Elf5 and Pea3 are expressed at different stages of
post-natal mammary gland development and the expression
pattern of Muc4 in the pregnant mammary gland most closely
resembles that of Elf5. The expression of both Elf5 and Muc4 is
induced at mid pregnancy, peaking early in lactation, and
diminishing during involution [reviewed in 3,5,26], whereas
Pea3 protein expression is highest during puberty and during
early pregnancy [reviewed in 28]. It therefore seems most likely
that Muc4 expression in the pregnant mammary gland is regulated
by Elf5 and not Pea3.
In rat mammary epithelial cells, Muc4 acts as a ligand for the
ErbB2 receptor [29]. It has been suggested that a Muc4/ErbB2
complex is involved in the maintenance and survival of alveolar
epithelial cells during pregnancy and that the downregulation of
Muc4 and ErbB2 expression during involution plays a role in the
initiation of apoptosis [30]. Although Muc4 protein is absent in
Elf5
+/2 mammary glands during pregnancy, we have previously
shown that there is no increase in apoptosis in Elf5
+/2 mammary
glands [3].
The formation of a complex between Muc4 and its receptor
ErbB2 on the surface of mammary epithelial cells triggers ErbB2
Elf5 Mammary Gland Development
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In polarised epithelial cells, ErbB2 resides on the basolateral
surface of the cell along with other ErbB receptors. The
association of Muc4 with ErbB2 leads to the translocation of
ErbB2 from the basolateral to the apical surface of the cell [31].
This repositioning effectively separates ErbB2 from its usual
heterodimerisation partner - ErbB3. ErbB2/ErbB3 dimers are
strong inducers of cellular proliferation [32], therefore the
separation of these proteins prevents downstream proliferation
signals from these receptors. The separation of ErbB2 from ErbB3
induced by Muc4 is thought to trigger the ‘switch’ from the
proliferative phase to the differentiation phase in mammary
epithelial cells [29,31].
The absence of Muc4 protein in the Elf5
+/2 gland would
abrogate the formation of the Muc4/ErbB2 complex and the
subsequent phosophorlation of ErbB2. Therefore it is likely that
the switch from proliferation to differentiation is not induced in
Elf5
+/2 mammary glands. However we did not observe excessive
proliferation in the Elf5
+/2 mammary glands. Rather, these glands
contained fewer alveolar structures than the wildtype gland.
Therefore there must be other mechanisms involved in the
cessation of mammary epithelial cell proliferation. Our data is
consistent with Elf5 acting as a controller of a switch to
differentiation, since robust expression of Elf5 protein in the
Elf5
+/2 mammary gland resulted in a marked shift in the
transcriptional profile of the gland and the first expression of milk
proteins – definitive markers of differentiation. We propose that
Elf5 controls this switch partly via its regulation of Muc4.
It is not unprecedented for an Ets family member to be involved
in the control of the cellular cues that drive proliferation versus
differentiation. Pea3 is a positive regulator of Muc4 expression in
pancreatic cancer cells, whilst also acting as a negative regulator of
ErbB2 [9]. Via its control of the balance between relative
expression levels of Muc4 and ErbB2, Pea3 is thought to promote
pancreatic cancer cell differentiation [9]. There is the possibility
that the delicate balance of proliferation and differentiation may
be a mechanism often driven by Ets factors.
Our hypothesis that Elf5 regulates the switch from mammary
epithelial cell proliferation to differentiation is supported by the
report of a mouse in which ectopic over-expression of Elf5 in the
mammary gland led to a reduction in epithelial proliferation and
forced differentiation of the mammary epithelium [19]. This
resulted in the expression of numerous milk proteins in non-
pregnant mammary glands [19]. This phenotype may have
occurred via a direct upregulation of Muc4 by Elf5 and the
subsequent termination of proliferative signals generated by ErbB2
and ErbB3 dimers on the basolateral surface of the epithelial cells.
The novel findings of our study give insight into a newly defined
role for Elf5 in the pregnant mammary gland. We hypothesise that
via the direct regulation of Muc4 expression, Elf5 co-ordinates the
switch between mammary epithelial cell proliferation and
differentiation during pregnancy, making it a master regulator of
cellular processes in this organ.
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